Sasa A. Zivkovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sasa A. Zivkovic has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
David Lacomis
Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Department of Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
6 shared publications- David Lacomis
University of Pittsburgh School of Medicine
3 shared publications Araya Puwanant
Department of Neurology, University of Pittsburgh Medical Center, 3471 Fifth Ave #810, Pittsburgh, PA 15213, United States
2 shared publicationsD. Lacomis
Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
2 shared publicationsSuzanne Lentzsch
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA
2 shared publicationsThomas A. Medsger
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
2 shared publications
Latest Publications
- 23 July 2019
- Published by Springer Nature
- p. 157-170
Neurological Emergencies in the Immunocompromised Population
- 23 July 2019
- Published by Springer Nature
- p. 157-170
Neurological Emergencies in the Immunocompromised Population
- 1 February 2019
- Published by Elsevier in Neuromuscular Disorders
- Vol. 29 (2) , 127-133
Clinical spectrum of neuromuscular complications after immune checkpoint inhibition
- 1 February 2019
- Published by Elsevier in Neuromuscular Disorders
- Vol. 29 (2) , 127-133
Clinical spectrum of neuromuscular complications after immune checkpoint inhibition
- 1 March 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27 (3) , 266-268
Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
- 1 March 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27 (3) , 266-268
Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
- Open Access
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 9 (3) , 126-130
Iatrogenic amyloid polyneuropathy after domino liver transplantation
Liver transplantation has been used in treatment of transthyretin amyloidosis, and some patients undergo domino liver transplantation (DLT) with explanted liver being transplanted to another patient with liver failure as the liver is otherwise usually functionally normal. Until end of 2015, there were 1154 DLT performed worldwide. DLT for transthyretin amyloidosis is associated with the risk of developing de novo systemic amyloidosis and amyloid neuropathy, and the risk may be greater with some non-Val30Met mutations. De novo amyloid neuropathy has been described in up to 23% of transplant recipients. Neuropathy may be preceded by asymptomatic amyloid deposition in various tissues and symptoms of neuropathy started after a median of 7 years following DLT (5.7 ± 3.2 years; range 2 mo to 10 years). Typical initial symptoms include neuropathic pain and sensory loss, while dysautonomia usually starts later. Progression of neuropathy may necessitate liver re-transplantation, and subsequent improvement of neuropathy has been reported in some patients. Explant allograft recipients need close monitoring for signs of systemic amyloidosis, neuropathy and dysautonomia as progressive symptoms may require re-transplantation.
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 9 (3) , 126-130
Open AccessIatrogenic amyloid polyneuropathy after domino liver transplantation
Liver transplantation has been used in treatment of transthyretin amyloidosis, and some patients undergo domino liver transplantation (DLT) with explanted liver being transplanted to another patient with liver failure as the liver is otherwise usually functionally normal. Until end of 2015, there were 1154 DLT performed worldwide. DLT for transthyretin amyloidosis is associated with the risk of developing de novo systemic amyloidosis and amyloid neuropathy, and the risk may be greater with some non-Val30Met mutations. De novo amyloid neuropathy has been described in up to 23% of transplant recipients. Neuropathy may be preceded by asymptomatic amyloid deposition in various tissues and symptoms of neuropathy started after a median of 7 years following DLT (5.7 ± 3.2 years; range 2 mo to 10 years). Typical initial symptoms include neuropathic pain and sensory loss, while dysautonomia usually starts later. Progression of neuropathy may necessitate liver re-transplantation, and subsequent improvement of neuropathy has been reported in some patients. Explant allograft recipients need close monitoring for signs of systemic amyloidosis, neuropathy and dysautonomia as progressive symptoms may require re-transplantation.
- 22 September 2015
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 133 (5) , 403-405
Spinal epidural abscess following treatment with rituximab
Spinal epidural abscess is a rare complication with potential severe morbidity, and continued vigilance is needed as timely intervention may prevent severe morbidity and potentially fatal outcome.
- 22 September 2015
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 133 (5) , 403-405
Spinal epidural abscess following treatment with rituximab
Spinal epidural abscess is a rare complication with potential severe morbidity, and continued vigilance is needed as timely intervention may prevent severe morbidity and potentially fatal outcome.
- 26 May 2015
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 15 (7) , 1-10
The Neurology of Solid Organ Transplantation
Transplantation is the rescue treatment for end-stage organ failure with more than 110,000 solid organs transplantations performed worldwide annually. Recent advances in transplantation procedures and posttransplantation management have improved long-term survival and quality of life of transplant recipients, shifting the focus from acute perioperative critical care needs toward long-term chronic medical problems. Neurologic complications affect up to 30–60 % of solid organ transplant recipients. Common etiologies include opportunistic infections and toxicities of antirejection medications, and wide spectrum of toxic and metabolic disturbances. Most complications are common to all allograft types, but some are relatively specific for individual allograft types (e.g., central pontine myelinolysis in liver transplant recipients). Close collaboration between neurologists and other transplant team members is essential for effective management. Early recognition of complications and accurate diagnosis leading to timely treatment is essential to reduce the morbidity and improve the overall transplant outcome.
- 26 May 2015
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 15 (7) , 1-10
The Neurology of Solid Organ Transplantation
Transplantation is the rescue treatment for end-stage organ failure with more than 110,000 solid organs transplantations performed worldwide annually. Recent advances in transplantation procedures and posttransplantation management have improved long-term survival and quality of life of transplant recipients, shifting the focus from acute perioperative critical care needs toward long-term chronic medical problems. Neurologic complications affect up to 30–60 % of solid organ transplant recipients. Common etiologies include opportunistic infections and toxicities of antirejection medications, and wide spectrum of toxic and metabolic disturbances. Most complications are common to all allograft types, but some are relatively specific for individual allograft types (e.g., central pontine myelinolysis in liver transplant recipients). Close collaboration between neurologists and other transplant team members is essential for effective management. Early recognition of complications and accurate diagnosis leading to timely treatment is essential to reduce the morbidity and improve the overall transplant outcome.
- 21 May 2015
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 133 (2) , 84-96
Intravenous immunoglobulin in the treatment of neurologic disorders
Intravenous immunoglobulins (IVIGs) are often used in the treatment of autoimmune disorders and immunodeficiencies, and it has been estimated that neurologic indications can account for up to 43% of IVIG used in clinical practice. In neurologic clinical practice, IVIG is used for acute therapy of newly diagnosed autoimmune disorders or exacerbations of pre-existing conditions, or as long-term maintenance treatment for chronic disorders. IVIG exerts its effects on humoral and cell-based immunity through multiple pathways, without a single dominant mechanism. Clinical use of IVIG has been supported by guidelines from American Academy of Neurology and European Federation of Neurologic Societies. IVIG is generally recommended for the treatment of Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy in adults, multifocal motor neuropathy and myasthenia gravis, and should be considered as a treatment option for dermatomyositis in adults and Lambert-Eaton myasthenic syndrome. Additional potential indications include stiff person syndrome, multiple sclerosis during pregnancy or while breastfeeding, refractory autoimmune epilepsy, and paraneoplastic disorders. Clinical use of IVIG is mostly safe but few adverse effects may still occur with potentially severe complications, including aseptic meningitis and thromboembolism. In addition to intravenous route (IVIG), subcutaneous immunoglobulins have been used as an alternative treatment option, especially in patients with limited intravenous access. Treatment with IVIG is effective in various autoimmune diseases, but its broader use is constrained by limited supply. This review evaluates the use of immunoglobulins in treatment of neurologic diseases.
- 21 May 2015
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 133 (2) , 84-96
Intravenous immunoglobulin in the treatment of neurologic disorders
Intravenous immunoglobulins (IVIGs) are often used in the treatment of autoimmune disorders and immunodeficiencies, and it has been estimated that neurologic indications can account for up to 43% of IVIG used in clinical practice. In neurologic clinical practice, IVIG is used for acute therapy of newly diagnosed autoimmune disorders or exacerbations of pre-existing conditions, or as long-term maintenance treatment for chronic disorders. IVIG exerts its effects on humoral and cell-based immunity through multiple pathways, without a single dominant mechanism. Clinical use of IVIG has been supported by guidelines from American Academy of Neurology and European Federation of Neurologic Societies. IVIG is generally recommended for the treatment of Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy in adults, multifocal motor neuropathy and myasthenia gravis, and should be considered as a treatment option for dermatomyositis in adults and Lambert-Eaton myasthenic syndrome. Additional potential indications include stiff person syndrome, multiple sclerosis during pregnancy or while breastfeeding, refractory autoimmune epilepsy, and paraneoplastic disorders. Clinical use of IVIG is mostly safe but few adverse effects may still occur with potentially severe complications, including aseptic meningitis and thromboembolism. In addition to intravenous route (IVIG), subcutaneous immunoglobulins have been used as an alternative treatment option, especially in patients with limited intravenous access. Treatment with IVIG is effective in various autoimmune diseases, but its broader use is constrained by limited supply. This review evaluates the use of immunoglobulins in treatment of neurologic diseases.
- 1 May 2014
- Published by Elsevier in Neuromuscular Disorders
- Vol. 24 (5) , 425-430
Localized scleroderma and regional inflammatory myopathy
- 1 May 2014
- Published by Elsevier in Neuromuscular Disorders
- Vol. 24 (5) , 425-430
Localized scleroderma and regional inflammatory myopathy
- 1 January 2014
- Published by Elsevier
- Vol. 121, 1305-1317
Neurologic aspects of multiple organ transplantation
- 1 January 2014
- Published by Elsevier
- Vol. 121, 1305-1317
Neurologic aspects of multiple organ transplantation
- Open Access
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 5 (8) , 409-16
Neurologic complications after liver transplantation
Neurologic complications are relatively common after solid organ transplantation and affect 15%-30% of liver transplant recipients. Etiology is often related to immunosuppressant neurotoxicity and opportunistic infections. Most common complications include seizures and encephalopathy, and occurrence of central pontine myelinolysis is relatively specific for liver transplant recipients. Delayed allograft function may precipitate hepatic encephalopathy and neurotoxicity of calcineurin inhibitors typically manifests with tremor, headaches and encephalopathy. Reduction of neurotoxic immunosuppressants or conversion to an alternative medication usually result in clinical improvement. Standard preventive and diagnostic protocols have helped to reduce the prevalence of opportunistic central nervous system (CNS) infections, but viral and fungal CNS infections still affect 1% of liver transplant recipients, and the morbidity and mortality in the affected patients remain fairly high. Critical illness myopathy may also affect up to 7% of liver transplant recipients. Liver insufficiency is also associated with various neurologic disorders which may improve or resolve after successful liver transplantation. Accurate diagnosis and timely intervention are essential to improve outcomes, while advances in clinical management and extended post-transplant survival are increasingly shifting the focus to chronic post-transplant complications which are often encountered in a community hospital and an outpatient setting.
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 5 (8) , 409-16
Open AccessNeurologic complications after liver transplantation
Neurologic complications are relatively common after solid organ transplantation and affect 15%-30% of liver transplant recipients. Etiology is often related to immunosuppressant neurotoxicity and opportunistic infections. Most common complications include seizures and encephalopathy, and occurrence of central pontine myelinolysis is relatively specific for liver transplant recipients. Delayed allograft function may precipitate hepatic encephalopathy and neurotoxicity of calcineurin inhibitors typically manifests with tremor, headaches and encephalopathy. Reduction of neurotoxic immunosuppressants or conversion to an alternative medication usually result in clinical improvement. Standard preventive and diagnostic protocols have helped to reduce the prevalence of opportunistic central nervous system (CNS) infections, but viral and fungal CNS infections still affect 1% of liver transplant recipients, and the morbidity and mortality in the affected patients remain fairly high. Critical illness myopathy may also affect up to 7% of liver transplant recipients. Liver insufficiency is also associated with various neurologic disorders which may improve or resolve after successful liver transplantation. Accurate diagnosis and timely intervention are essential to improve outcomes, while advances in clinical management and extended post-transplant survival are increasingly shifting the focus to chronic post-transplant complications which are often encountered in a community hospital and an outpatient setting.